International certification and testing services provider SGS announced that it has acquired Scottish testing company Vitrology for an undisclosed sum.
The acquisition will open the door for Vitrology to enter SGS' life sciences network that extends to more than 1,300 offices and laboratories around the world, from North America, to Europe and Asia. Just prior to the acquisition, the 5-year-old Vitrology had one lab in Glasgow and employed 38 employees and sales agents in North America and Asia, according to Herald Scotland.
"This is an exciting opportunity to provide a full service offer across Europe, Americas and Asia focused on biologics and vaccines, and enhances SGS' current portfolio in bioanalysis, cell-based and immunoassays, quality control and Phase I to IV clinical trial services," said Vitrology CEO Margaret Temple.
Picking up a company as seemingly small as Vitrology may not sound like it could make a dent into one as large as SGS, but it will build SGS' biologic therapeutics strategy, said CEO Chris Kirk in a statement. Vitrology can offer custom development of assays, regulatory and safety consultancy services and raw material and bulk harvest testing, among other services, according to SGS.
"We are now among the top global players," according to Kirk. "It creates an ideal platform for further deployment in virology and molecular biology activities, to be leveraged within our global network."
- read the SGS release
- get more from Herald Scotland